Showing results (81-90 of 104) with videos related to
Sort By:
Pageof 11
Journal of Comparative Effectiveness Research|June 5, 2018
Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in ChinaWen Chen, Thomas Ward, Mai Ping Tan, et al.Pharmacoeconomics - Open|December 6, 2024
Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year DataAlison D Griffiths, Robert O Young, Yong Yuan, et al.Journal of Medical Economics|December 20, 2019
Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithmNathan R Hill, Belinda Sandler, Ruth Mokgokong, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 3, 2016
Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapiesHayley Bennett, Jason Gordon, Beverley Jones, et al.BMC Cancer|July 19, 2020
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UKRobert Hawkins, Kate Fife, Michael Hurst, et al.Clinical Drug Investigation|September 3, 2016
Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver DiseaseThomas Ward, Jason Gordon, Beverley Jones, et al.Pharmacoeconomics|November 24, 2023
Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling StudyJason Gordon, Maria Gheorghe, Cale Harrison, et al.International Journal of Antimicrobial Agents|May 15, 2025
Antimicrobial resistance trends, predictors, and burden in England: a retrospective study using the Clinical Practice Research Datalink from 2015 to 2021Amer Taie, Maria Gheorghe, James Amos, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 11, 2020
Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial ProgrammeJason Gordon, Thomas Danne, Lee Beresford-Hulme, et al.European Journal of Gastroenterology & Hepatology|November 11, 2016
A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspectivePhil McEwan, Nowlan Selvapatt, Ashley Brown, et al.Pageof 11